top of page
IBCC-RCSI-2027_Primary_CMYK_Logo.jpg

Laura Esserman

Laura Esserman, MD, MBA, an internationally recognized breast surgeon, breast oncology specialist, and visionary in personalized medicine, is revolutionizing breast cancer screening and treatment throughout our nation today. Her breast cancer work spans a spectrum from basic science to public policy issues and the impact of both on the delivery of clinical care. She is a provocative thought leader calling attention to, and finding solutions for, over-diagnosis and over-treatment of breast cancer, especially of Ductal Carcinoma In Situ (DCIS) a non-invasive, early-stage breast cancer precursor.

​

Since 2002, Dr. Esserman has led the I-SPY TRIALs, a ground-breaking national public-private collaboration among NCI, FDA, more than 45 cancer research centers, and over 30 major pharma and biotech companies. This trial model, which has now become an international model for translational research, is designed to shave several years and tens of millions of dollars off the drug development process. The trial paradigm is now being developed for use in other disease domains, including DCIS, and COVID/ARDS, and other cancers.  She is founder and board member of the not-for-profit organization, Quantum Leap Healthcare Collaborative, the sponsor of the I-SPY TRIALs, dedicated to integrating care and research.

​

Additionally, Dr. Esserman led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research from screening through treatment and outcomes.  As part of the network, she has spearheaded the development of the WISDOM Study to learn how to improve breast cancer screening by testing and comparing the safety and efficacy of a personalized risk assessment to inform and guide a screening and prevention strategy against the standard of annual screening in over 100,000 women.

​

Dr. Esserman has published more than 500 articles in peer-reviewed journals, and is regularly consulted by prestigious scientific, business, and consumer media including The New York Times, Wall Street Journal, Stat News, Los Angeles Times, Health Magazine, Prevention Magazine, The Newshour, ABC World News, the NBC Nightly News, the CBS Evening News, and NPR’s Science Friday.

She was included as one of TIME Magazine’s 100 Most Influential People of 2016, and has received  numerous awards, including the Giant of Cancer Care® in Cancer Diagnostics award, the Ernest C. Arbuckle Award from Stanford Business School, and the Komen Brinker Award for Scientific Distinction in Clinical Research, the Simon Shubitz Cancer Prize and Lectureship,  and the American Italian Prize for Scientific Excellence in Medicine.

Laura Esserman
bottom of page